Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 7, 2026, 3:06 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 49–72 of 130 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Subjects With Hyperlipidemia, Dyslipidemia Clear all
Completed Phase 1 Interventional

Study to Investigate Safety, Tolerability, PK and PD Response of SLN360 in Subjects With Elevated Lipoprotein(a)

NCT04606602
View directory record Official record
Conditions
Hyperlipidemias, Dyslipidemias, Elevated Lp(a)
Interventions
SLN360, Placebo
Drug
Lead sponsor
Silence Therapeutics plc
Industry
Eligibility
18 Years and older
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
4
States / cities
Jacksonville, Florida • Port Orange, Florida • Cincinnati, Ohio + 1 more
Source: ClinicalTrials.gov public record
Updated Aug 12, 2024 · Synced Oct 7, 2026, 3:06 AM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers

Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), and Pharmacodynamics (PD) of Liposomal siRNA in Subjects With High Cholesterol

NCT00927459
View directory record Official record
Conditions
Hypercholesterolemia
Interventions
PRO-040201, Placebo
Drug
Lead sponsor
Arbutus Biopharma Corporation
Industry
Eligibility
18 Years to 65 Years
Enrollment
23 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2010
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Jan 22, 2010 · Synced Oct 7, 2026, 3:06 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Pharmacokinetic and Pharmacodynamic Study of PF-04950615 (RN316) in Subjects With Hypercholesterolemia

NCT01435382
View directory record Official record
Conditions
Hypercholesterolemia, Dyslipidemias, Hyperlipidemias, Lipid Metabolism Disorders, Metabolic Diseases
Interventions
PF-04950615 (RN316)
Biological
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
49 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
7
States / cities
Chula Vista, California • Miami, Florida • Overland Park, Kansas + 4 more
Source: ClinicalTrials.gov public record
Updated Jul 23, 2018 · Synced Oct 7, 2026, 3:06 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Safety And Tolerability Of Multiple Doses Of PF-04950615 (RN316) In Subjects With Hypercholesterolemia

NCT01243151
View directory record Official record
Conditions
Hypercholesterolemia, Dyslipidemia
Interventions
PF-04950615 (RN316)
Biological
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 80 Years
Enrollment
68 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011
U.S. locations
9
States / cities
Culver City, California • Glendale, California • Miami, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Jan 22, 2019 · Synced Oct 7, 2026, 3:06 AM EDT
Completed Phase 2Phase 3 Interventional Results available

Trial Evaluating PCSK9 Antibody in Subjects With LDL Receptor Abnormalities

NCT01588496
View directory record Official record
Conditions
Homozygous Familial Hypercholesterolemia
Interventions
Evolocumab, Placebo
Biological · Drug
Lead sponsor
Amgen
Industry
Eligibility
12 Years to 80 Years
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
2
States / cities
New York, New York • Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Nov 29, 2018 · Synced Oct 7, 2026, 3:06 AM EDT
Completed Phase 3 Interventional Results available

Reduction of LDL-C With PCSK9 Inhibition in Heterozygous Familial Hypercholesterolemia Disorder Study-2

NCT01763918
View directory record Official record
Conditions
Hyperlipidemia
Interventions
Evolocumab, Placebo
Biological · Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 80 Years
Enrollment
331 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013
U.S. locations
2
States / cities
Scottsdale, Arizona • Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Jun 17, 2019 · Synced Oct 7, 2026, 3:06 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study Testing A Radioactive Compound Given Through A Vein With And Without The Non-Radioactive Compound, Given By Mouth, To Characterize Tissue Distribution Using Positron Emission Tomography Scanning

NCT02410525
View directory record Official record
Conditions
Healthy
Interventions
[11C]PF-06427878, PF-06427878 10 mg, PF-06427878 600 mg
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 55 Years · Male only
Enrollment
8 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015
U.S. locations
3
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Oct 29, 2015 · Synced Oct 7, 2026, 3:06 AM EDT
Terminated Phase 3 Interventional

A Clinical Trial Comparing Torcetrapib/Atorvastatin To Simvastatin In Subjects With High Cholesterol (A5091031).

NCT00267280
View directory record Official record
Conditions
Hyperlipidemia, Dyslipidemia, Hypercholesterolemia
Interventions
torcetrapib/atorvastatin, simvastatin
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
640 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006
U.S. locations
51
States / cities
Birmingham, Alabama • Mesa, Arizona • Alhambra, California + 48 more
Source: ClinicalTrials.gov public record
Updated Feb 17, 2012 · Synced Oct 7, 2026, 3:06 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Pharmacokinetic Study of Diazoxide Choline in Hypertriglyeridemic Subjects

NCT01211860
View directory record Official record
Conditions
Hypertriglyceridmia
Interventions
Diazoxide Choline Controlled-Release Tablet
Drug
Lead sponsor
Essentialis, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
9 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010
U.S. locations
1
States / cities
Fargo, North Dakota
Source: ClinicalTrials.gov public record
Updated Jan 10, 2014 · Synced Oct 7, 2026, 3:06 AM EDT
Completed Phase 3 Interventional

Lipitor Trial To Study The Effect Of Torcetrpib/Atorvastatin To Atorvastatin Alone.

NCT00137462
View directory record Official record
Conditions
Hyperlipidemia
Interventions
torcetrapib/atorvastatin, atorvastatin
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
900 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
48
States / cities
Huntsville, Alabama • Union Grove, Alabama • Fresno, California + 40 more
Source: ClinicalTrials.gov public record
Updated Nov 16, 2007 · Synced Oct 7, 2026, 3:06 AM EDT
Completed Phase 3 Interventional Results available

Goal Achievement After Utilizing an Anti-PCSK9 Antibody in Statin Intolerant Subjects -2

NCT01763905
View directory record Official record
Conditions
Hyperlipidemia
Interventions
Evolocumab, Placebo to Evolocumab, Ezetimibe, Placebo to Ezetimibe
Biological · Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 80 Years
Enrollment
307 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013
U.S. locations
20
States / cities
Carmichael, California • Los Angeles, California • Mission Viejo, California + 15 more
Source: ClinicalTrials.gov public record
Updated Jul 20, 2020 · Synced Oct 7, 2026, 3:06 AM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Lipoprotein Interactions and Platelet Function in Healthy Individuals and Those With Lipid Disorders

NCT06747000
View directory record Official record
Conditions
Lipid Disorders
Interventions
Not listed
Lead sponsor
The Miriam Hospital
Other
Eligibility
18 Years to 69 Years
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2029
U.S. locations
2
States / cities
East Providence, Rhode Island • Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Oct 1, 2025 · Synced Oct 7, 2026, 3:06 AM EDT
Active, not recruiting Phase 3 Interventional

A Phase 3 Study of Zodasiran in Adolescent and Adult Subjects With Homozygous Familial Hypercholesterolemia (YOSEMITE)

NCT07037771
View directory record Official record
Conditions
Homozygous Familial Hypercholesterolemia
Interventions
zodasiran Injection, Placebo
Drug
Lead sponsor
Arrowhead Pharmaceuticals
Industry
Eligibility
12 Years and older
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
4
States / cities
Park Ridge, Illinois • New York, New York • Cincinnati, Ohio + 1 more
Source: ClinicalTrials.gov public record
Updated Aug 12, 2026 · Synced Oct 7, 2026, 3:06 AM EDT
Completed Phase 2 Interventional Results available

Study of ISIS 703802 in Participants With Hypertriglyceridemia, Type 2 Diabetes Mellitus, and Nonalcoholic Fatty Liver Disease

NCT03371355
View directory record Official record
Conditions
NAFLD, Diabetes Mellitus, Type 2, Hypertriglyceridemia, Fatty Liver, Nonalcoholic
Interventions
Placebo, ISIS 703802 40 mg, ISIS 703802 80 mg, ISIS 703802 20 mg
Drug
Lead sponsor
Akcea Therapeutics
Industry
Eligibility
18 Years to 70 Years
Enrollment
105 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
38
States / cities
Chandler, Arizona • Fountain Hills, Arizona • Glendale, Arizona + 30 more
Source: ClinicalTrials.gov public record
Updated Feb 1, 2021 · Synced Oct 7, 2026, 3:06 AM EDT
Completed Not applicable Interventional

Regeneron 1331 Kinetics Sub-Study HoFH

NCT04722068
View directory record Official record
Conditions
Hypercholesterolemia, Familial
Interventions
Kinetics test
Other
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 17, 2021 · Synced Oct 7, 2026, 3:06 AM EDT
Completed Phase 3 Interventional

Safety and Effectiveness of Fenofibrate and Pravastatin in HIV-Positive Patients With Abnormal Blood Lipids

NCT00006412
View directory record Official record
Conditions
HIV Infections, Lipodystrophy
Interventions
Pravastatin sodium, Fenofibrate
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
630 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 2003
U.S. locations
57
States / cities
Birmingham, Alabama • Los Angeles, California • Menlo Park, California + 33 more
Source: ClinicalTrials.gov public record
Updated Nov 1, 2021 · Synced Oct 7, 2026, 3:06 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Evaluation of 3-V Bioscience-2640 to Reduce de Novo Lipogenesis in Subjects With Characteristics of Metabolic Syndrome

NCT02948569
View directory record Official record
Conditions
Metabolic Syndrome
Interventions
3-V Bioscience-2640
Drug
Lead sponsor
University of Missouri-Columbia
Other
Eligibility
35 Years to 60 Years · Male only
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Columbia, Missouri
Source: ClinicalTrials.gov public record
Updated May 4, 2025 · Synced Oct 7, 2026, 3:06 AM EDT
Completed Phase 3 Interventional Results available

A Randomized, Double-blind, Placebo Controlled Study to Assess Efficacy, Safety and Tolerability of LCQ908 in Subjects With Familial Chylomicronemia Syndrome

NCT01514461
View directory record Official record
Conditions
Familial Chylomicronemia Syndrome (FCS)
Interventions
LCQ908, Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Seatlle, Washington
Source: ClinicalTrials.gov public record
Updated Jun 3, 2015 · Synced Oct 7, 2026, 3:06 AM EDT
Completed Phase 2 Interventional Results available

Open-Label Study To Evaluate MN-001 on HDL & Triglyceride in NASH & NAFLD Subjects

NCT02681055
View directory record Official record
Conditions
Non-alcoholic Steatohepatitis, Hypertriglyceridemia, Non-alcoholic Fatty Liver Disease, Hypercholesterolemia
Interventions
MN-001
Drug
Lead sponsor
MediciNova
Industry
Eligibility
18 Years and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
3
States / cities
Coronado, California • La Jolla, California • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Mar 15, 2023 · Synced Oct 7, 2026, 3:06 AM EDT
Completed Phase 2 Interventional

A Study in People With High Cholesterol

NCT00133380
View directory record Official record
Conditions
Hypercholesterolemia
Interventions
PPAR alpha, atorvastatin, placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 80 Years
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
28
States / cities
Fayetteville, Arkansas • Stockton, California • Highlands Ranch, Colorado + 25 more
Source: ClinicalTrials.gov public record
Updated Apr 6, 2007 · Synced Oct 7, 2026, 3:06 AM EDT
Completed Not applicable Interventional

Trial of Two Dietary Programs on Cardiometabolic Risk Factors in Subjects With Metabolic Syndrome

NCT01010841
View directory record Official record
Conditions
Metabolic Syndrome, Overweight, Obesity, Hypercholesterolemia
Interventions
UltraMealPlus 360 (Medical food), Low-glycemic-load diet
Dietary Supplement · Other
Lead sponsor
MetaProteomics LLC
Industry
Eligibility
20 Years to 75 Years · Female only
Enrollment
89 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Jan 12, 2012 · Synced Oct 7, 2026, 3:06 AM EDT
Terminated Phase 3 Interventional

A Clinical Trial Comparing Torcetrapib/Atorvastatin to Ezetimibe/Simvastatin In Subjects With A Cholesterol Disorder.

NCT00267267
View directory record Official record
Conditions
Hyperlipidemia, Dyslipidemia
Interventions
torcetrapib/atorvastatin, ezetimibe/simvastatin
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
1,784 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
123
States / cities
Birmingham, Alabama • Chandler, Arizona • Mesa, Arizona + 100 more
Source: ClinicalTrials.gov public record
Updated Dec 10, 2007 · Synced Oct 7, 2026, 3:06 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study to Evaluate the Safety, PK, and Pharmacodynamics of LIB003

NCT03545438
View directory record Official record
Conditions
Hypercholesterolemia
Interventions
LIB003
Biological
Lead sponsor
LIB Therapeutics LLC
Industry
Eligibility
18 Years to 70 Years
Enrollment
63 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Jul 27, 2018 · Synced Oct 7, 2026, 3:06 AM EDT
Completed Phase 3 Interventional Results available

Monoclonal Antibody Against PCSK9 to Reduce Elevated LDL-C in Subjects Currently Not Receiving Drug Therapy for Easing Lipid Levels-2

NCT01763827
View directory record Official record
Conditions
Hyperlipidemia
Interventions
Evolocumab, Ezetimibe, Placebo to Evolocumab, Placebo to Ezetimibe
Biological · Drug · Other
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 80 Years
Enrollment
615 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013
U.S. locations
47
States / cities
Birmingham, Alabama • Chandler, Arizona • Little Rock, Arkansas + 40 more
Source: ClinicalTrials.gov public record
Updated Nov 8, 2022 · Synced Oct 7, 2026, 3:06 AM EDT